Our focus is to treat diseases that cause severe pain and to bring to market non-addictive pain medications. We’re starting with Peripheral Artery Disease (PAD), a painful condition affecting over 8.5 million Americans.
As we work towards Phase 2b trials for our PAD treatment, we have another goal in mind. Treat diseases at the source and reduce the need for opioid prescriptions.
A world without pain is just over the horizon.
So is a new JanOne.
We’re launching our new website soon.
JanOne sees every day as an opportunity for fresh ideas to end the opioid epidemic, the worst drug crisis in our nation’s history.
As a NASDAQ-listed company, JanOne draws private-sector resources into this urgent fight. We seek innovative treatments—focusing on developing revolutionary, non-addictive drugs that kill pain, not people.
An important initiative!
We have a phenomenal team developing a treatment for Peripheral Artery Disease (PAD) and to remove the need to prescribe opioids for associated pain. I’m determined to do my part to help make a difference with JanOne (NASDAQ: JAN).
#KillPainNotPeople
Many people who have been prescribed opioids hang on to any leftovers, just in case they need them in the future. But this practice can have deadly consequences if children or pets accidentally ingest these drugs.
https://www.mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/opioid-disposal/art-20381382
A growing number of doctors are unwilling to prescribe opioids for pain. That is why it is JanOne's mission to find alternatives to opiates pain medications that will treat the real causes of pain for diseases such as PAD.
https://local21news.com/news/the-opioid-crisis-finding-hope/growing-number-of-doctors-no-longer-prescribing-opioids
